Trends in home phototherapy adoption in the US: Monetary disincentives are only the tip of the iceberg

Journal of Dermatological Treatment

Volumn 22, Issue 1, 2011, Pages 27-30

  Yentzer, Brad A ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Copay; Cost; Deductible; Insurance; Prescriptions; UVB

Indexed keywords

ETANERCEPT;

ARTICLE; CONTROLLED STUDY; DERMATOLOGY; HEALTH CARE COST; HOME CARE; HUMAN; PHOTOTHERAPY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REIMBURSEMENT; UNITED STATES;

EQUIPMENT AND SUPPLIES; FEES AND CHARGES; HUMANS; INSURANCE COVERAGE; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; SELF CARE; ULTRAVIOLET THERAPY;

EID: 78650951146     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903440080     Document Type: Article

References (6)

1. Miller DW, Feldman SR. Cost-effectiveness of moderate-tosevere psoriasis treatment. Expert Opin Pharmacother. 2006; 7:157-167.
2. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006;17: 359-361.
3. Simpson JF, Yelverton CB, Balkrishnan R, Fleischer A Jr, Lide W, Feldman SR. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis. Manag Care Interface. 2006; 19:39-43.
4. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61:11-21.
5. Feldman SR, Koo JY, Lebwohl MG, Menter A, Van Voorhees A. The psoriasis and psoriatic arthritis pocket guide: Treatment algorithms and management options. Portland, OR: National Psoriasis Foundation; 2005.
6. Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 2002;46:557-559.